国际肿瘤学杂志

国际肿瘤学杂志››2017,Vol. 44››Issue (1): 57-59.doi:10.3760/cma.j.issn.1673422X.2017.01.015

• 综述 •上一篇下一篇

抗血管生成药物联合EGFR-TKI在晚期NSCLC治疗中的应用

屈丽岩,康晓艳,宋霞

  1. 030013太原，山西医科大学附属肿瘤医院呼吸二病区
  • 出版日期:2017-01-08发布日期:2016-12-07
  • 通讯作者:宋霞，Email: songxia76@hotmail.com E-mail:songxia76@hotmail.com

Appliation of the combination of antiangiogenic agents and EGFR-TKIs in advanced NSCLC treatment

Qu Liyan, Kang Xiaoyan, Song Xia

  1. Second Ward of Department of Respiratory, Affiliated Cancer Hospital of Shanxi Medical University, Taiyuan 030013, China
  • Online:2017-01-08Published:2016-12-07
  • Contact:Song Xia, Email: songxia76@hotmail.com E-mail:songxia76@hotmail.com

PDF

1328

被引次数

1

摘要：表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）和抗血管生成药物在治疗晚期非小细胞肺癌（NSCLC）方面都已被证实临床获益。近年来研究表明，抗EGFR和抗血管生成药物联合能进一步提高晚期NSCLC的治疗疗效，甚至可以缓解EGFR-TKI耐药现象。根据抗血管生成药物的不同分类，目前临床研究主要包括抗血管内皮生长因子的单克隆抗体贝伐珠单抗联合EGFR-TKI和多靶点抗血管生成的酪氨酸激酶抑制剂联合EGFR-TKI，其中前者的研究结果在安全性和效果方面尤为理想，因而有望成为部分晚期NSCLC患者新的治疗标准。

关键词:癌,非小细胞肺,血管生成抑制剂,表皮生长因子受体-酪氨酸激酶抑制剂

Abstract:Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) and anti-angiogenic drugs have individually demonstrated clinical benefit in the treatment of patients with advanced non-small cell lung cancer (NSCLC). Recent studies demonstrate that the combination of anti-EGFR and anti-angiogenesis can more significantly enhance clinical benefit, and even can remit EGFR-TKIs resistance in the treatment of advanced NSCLC. According to the different kinds of antiangiogenesis drugs, recent clinical studies mainly include the combination of antivascular endothelial growth factor monoclonal antibody bevacizumab plus EGFR-TKIs and multi-targeted receptor antiangiogenic tyrosine kinase inhibitor plus EGFR-TKIs, and the former results show a more significant improvement in terms of safety and efficacy in the treatment of advanced NSCLC. Therefore, the combination of bevacizumab plus EGFR-TKIs can be used as a new treatment standard in the treatment of some patients with NSCLC.

Key words:Carcinoma, non-small-cell lung,Angiogenesis inhibitors,Epidermal growth factor receptor-tyrosine kinase inhibitors